Hudson Bay Capital Management
MRKR icon

Hudson Bay Capital Management’s Marker Therapeutics MRKR Stock Holding History

Hudson Bay Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-499,730
Closed -$615K – 1563
2025
Q1 		$615K Buy
499,730
+168,060
+51% +$308K ﹤0.01% 1004
2024
Q4 		$958K Buy
+331,670
New +$1.17M ﹤0.01% 758

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
I
INVST Indianapolis, Indiana $886M AUM 21.79% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Hudson Bay Capital Management's MRKR Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Marker Therapeutics (MRKR) in Q2 2025, closing a stake of 499,730 shares — an estimated $615K sold.

Hudson Bay Capital Management first reported a position in MRKR in Q4 2024 and held it in 2 quarters. The position peaked at $958K in Q4 2024. 31 funds tracked by Wall St. Rank hold MRKR as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining Marker Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 499,730 Marker Therapeutics shares in Q2 2025, an estimated $615K.
  • Hudson Bay Capital Management first reported a position in Marker Therapeutics in Q4 2024 and held it in 2 quarters.
  • Hudson Bay Capital Management's Marker Therapeutics position peaked at $958K in Q4 2024.
  • 31 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.